Michael Kyriakides
Investment Partner
Michael Kyriakides is an Investment Partner of Syncona Investment Management Ltd.
He works closely with Syncona portfolio companies Freeline Therapeutics, Purespring Therapeutics, Beacon Therapeutics and Clade Therapeutics. He previously also supported Nightstar Therapeutics and Gyroscope Therapeutics. Prior to joining Syncona, Michael was a member of the Life Sciences team at L.E.K. Consulting and a clinical project and NMR manager in the Faculty of Medicine at Imperial College London. Michael obtained his doctorate degree in toxicology and metabolic profiling at Imperial College London.
Syncona portfolio companies
- Freeline Therapeutics
- Clade Therapeutics (Board observer)
- Purespring Therapeutics (Board member)
- Beacon Therapeutics (Board observer)
